Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a widely explored therapeutic target in solid tumors. We evaluated the efficacy and safety of trastuzumab-pkrb, a biosimilar of trastuzumab, in combination with paclitaxel, in HER2-positive recurrent or metastatic urothelial carcinoma (U...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, M., Lee, J.L., Shin, S.J., Bae, W.K., Lee, H.J., Byun, J.H., Choi, Y.J., Youk, J., Ock, C.Y., Kim, S., Song, H., Park, K.H., Keam, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485395/
https://www.ncbi.nlm.nih.gov/pubmed/37385153
http://dx.doi.org/10.1016/j.esmoop.2023.101588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485395/
https://www.ncbi.nlm.nih.gov/pubmed/37385153
http://dx.doi.org/10.1016/j.esmoop.2023.101588

Ejemplares similares